The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2016Small Molecule Inhibitors of C-Abl for Parkinson's Disease Modification
Study Rationale:
Abelson tyrosine kinase (c-Abl) is believed to drive the deleterious events leading to loss of dopamine neurons in people with Parkinson's disease. This project will identify small... -
Research Grant, 2016Antibody Development for Modified Parkin Proteins Identified in the Human Brain
Study Rationale:
The PARK2 gene encodes the Parkin protein. It is one of three genes that protect from young-onset Parkinson disease (PD); in Parkin's absence, symptoms and signs usually begin before... -
Target Advancement Program, 2016Validation of the 18kDa Translocator Protein as a Novel Immunomodulator to Slow Progression in Parkinson's Disease
Study Rationale:
The immune system in the brain has two distinct modes: mode one is fighting infection and mode two is repairing injured nerve cells. In Parkinson's disease (PD), we think that the... -
Research Grant, 2016Effect of Parkin on Mitochondrial Protein Expression
Study Rationale:
Mutations in the gene encoding the protein parkin cause an inherited form of Parkinson's disease (PD). Parkin plays a neuroprotective role in response to stresses that affect the... -
Target Advancement Program, 2016Evaluation of the Parkin Pathway to Study Neural Mitophagy
Study Rationale:
Parkin is a protein that is disrupted in early onset Parkinson's disease and is believed to function in a cell-protective pathway (called mitophagy), which eliminates faulty... -
Research Grant, 2016Investigative Safety Study in LRRK2 Pre-clinical Models
Objective/Rationale:
Alternations in kidney function have been observed in pre-clinical models of LRRK2 that may represent potential safety liabilities of LRRK2 kinase inhibitor therapeutics for the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.